- AU$88.60m
- AU$76.02m
- AU$91.68m
- 79
- 69
- 70
- 82
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 36.28 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.87 | ||
| Price to Tang. Book | 3.26 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.88 | ||
| EV to EBITDA | 22.07 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -8.11% | ||
| Return on Equity | -15.51% | ||
| Operating Margin | -4.21% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 57.31 | 62.71 | 72.58 | 83.62 | 91.68 | 107.6 | 116.25 | 9.25% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +333.33 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SomnoMed Limited is an Australia-based company engaged in producing and selling devices for the oral treatment of sleep-related disorders. It provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is focused on the commercialization of the SomnoDent Mandibular Advancement Splint and other oral devices for sleep related disorders. Its segments include North America, Europe, Asia Pacific, CORE, and RSS. Its SomnoDent product line includes SomnoDent Avant, SomnoDent Classic, SomnoDent Flex, SomnoDent Fusion, Herbst Advance Elite and Herbst Advance. Its SomMorning Repositioner is designed to help return their mandible back to its pre-treatment centric position. Its SomnoBrux Michigan splint is a custom fit, acrylic splint (dental guard) for upper teeth designed to protect the teeth from grinding and scraping during Bruxism. It also offers SomTabs, which are cleaning tablets that are developed to clean oral appliances.
Directors
- Guy Russo NEC
- Kien Nguyen PRE
- Neil Robert Verdal-Austin CEO
- Herve Fievet CFO
- James Evanger CEX
- Matthew Conlon EVP
- Christopher Bedford VPR
- Terence Flitcroft SEC
- Hamish Corlett DRC
- Amrita Blickstead NED
- Karen Borg NED
- Hilton Brett NED
- Michael Gordon NED
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 16th, 1987
- Public Since
- August 27th, 2004
- No. of Shareholders
- 1,390
- No. of Employees
- 300
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 216,108,253
- Address
- Level 3, 20 Clarke St, Crows Nest, SYDNEY, 2065
- Web
- https://somnomed.com/en/
- Phone
- +61 294670400
- Auditors
- BDO Audit Pty Ltd
Upcoming Events for SOM
Similar to SOM
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
Aroa Biosurgery
Australian Stock Exchange - SEATS
FAQ
What is the SomnoMed share price?
As of Today at 23:20 UTC, shares in SomnoMed are trading at AU$0.41. This share price information is delayed by 15 minutes.
How has the SomnoMed share price performed this year?
Shares in SomnoMed last closed at AU$0.41 and the price had moved by +95.24% over the past 365 days. In terms of relative price strength the SomnoMed share price has outperformed the ASX All Ordinaries Index by +88.16% over the past year.
What are the analyst and broker recommendations for SomnoMed?
The overall consensus recommendation for SomnoMed is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the SomnoMed dividend yield?
SomnoMed does not currently pay a dividend.
Does SomnoMed pay a dividend?
SomnoMed does not currently pay a dividend.
When does SomnoMed next pay dividends?
SomnoMed does not currently pay a dividend.
How do I buy SomnoMed shares?
To buy shares in SomnoMed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of SomnoMed?
As of the previous close price of AU$0.41, shares in SomnoMed had a market capitalisation of AU$88.60m.
Where are SomnoMed shares listed?
Here are the trading details for SomnoMed:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: SOM
What kind of share is SomnoMed?
Based on an overall assessment of its quality, value and momentum SomnoMed is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a SomnoMed share price forecast for 2025?
The analyst consensus target price for shares in SomnoMed is AU$0.80. That is 95.12% above the last closing price of AU$0.41.
Analysts covering SomnoMed currently have a consensus Earnings Per Share (EPS) forecast of AU$0.00 for the next financial year.
Find out moreWhat is the trend in the SomnoMed share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SomnoMed. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +24.05%.
As of the last closing price of AU$0.41, shares in SomnoMed were trading -4.09% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the SomnoMed PE Ratio?
The SomnoMed PE ratio based on its reported earnings over the past 12 months is 36.28. The shares last closed at AU$0.41.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of SomnoMed?
SomnoMed's management team is headed by:
- Guy Russo - NEC
- Kien Nguyen - PRE
- Neil Robert Verdal-Austin - CEO
- Herve Fievet - CFO
- James Evanger - CEX
- Matthew Conlon - EVP
- Christopher Bedford - VPR
- Terence Flitcroft - SEC
- Hamish Corlett - DRC
- Amrita Blickstead - NED
- Karen Borg - NED
- Hilton Brett - NED
- Michael Gordon - NED